Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   283.69 (-1.13%)
AAPL   144.06 (-2.73%)
MSFT   241.55 (-2.40%)
META   109.16 (-2.02%)
GOOGL   95.92 (-1.58%)
AMZN   93.88 (+0.50%)
TSLA   184.07 (+0.66%)
NVDA   159.61 (-1.90%)
NIO   10.23 (+0.59%)
BABA   75.83 (+0.44%)
AMD   73.21 (-2.57%)
T   18.84 (-1.46%)
MU   56.08 (-3.99%)
CGC   3.40 (-7.10%)
F   13.71 (-2.63%)
GE   85.95 (-2.48%)
DIS   96.12 (-2.78%)
AMC   7.15 (-4.79%)
PYPL   80.55 (+0.59%)
PFE   49.34 (+0.26%)
NFLX   282.60 (-1.03%)
QQQ   283.69 (-1.13%)
AAPL   144.06 (-2.73%)
MSFT   241.55 (-2.40%)
META   109.16 (-2.02%)
GOOGL   95.92 (-1.58%)
AMZN   93.88 (+0.50%)
TSLA   184.07 (+0.66%)
NVDA   159.61 (-1.90%)
NIO   10.23 (+0.59%)
BABA   75.83 (+0.44%)
AMD   73.21 (-2.57%)
T   18.84 (-1.46%)
MU   56.08 (-3.99%)
CGC   3.40 (-7.10%)
F   13.71 (-2.63%)
GE   85.95 (-2.48%)
DIS   96.12 (-2.78%)
AMC   7.15 (-4.79%)
PYPL   80.55 (+0.59%)
PFE   49.34 (+0.26%)
NFLX   282.60 (-1.03%)
QQQ   283.69 (-1.13%)
AAPL   144.06 (-2.73%)
MSFT   241.55 (-2.40%)
META   109.16 (-2.02%)
GOOGL   95.92 (-1.58%)
AMZN   93.88 (+0.50%)
TSLA   184.07 (+0.66%)
NVDA   159.61 (-1.90%)
NIO   10.23 (+0.59%)
BABA   75.83 (+0.44%)
AMD   73.21 (-2.57%)
T   18.84 (-1.46%)
MU   56.08 (-3.99%)
CGC   3.40 (-7.10%)
F   13.71 (-2.63%)
GE   85.95 (-2.48%)
DIS   96.12 (-2.78%)
AMC   7.15 (-4.79%)
PYPL   80.55 (+0.59%)
PFE   49.34 (+0.26%)
NFLX   282.60 (-1.03%)
QQQ   283.69 (-1.13%)
AAPL   144.06 (-2.73%)
MSFT   241.55 (-2.40%)
META   109.16 (-2.02%)
GOOGL   95.92 (-1.58%)
AMZN   93.88 (+0.50%)
TSLA   184.07 (+0.66%)
NVDA   159.61 (-1.90%)
NIO   10.23 (+0.59%)
BABA   75.83 (+0.44%)
AMD   73.21 (-2.57%)
T   18.84 (-1.46%)
MU   56.08 (-3.99%)
CGC   3.40 (-7.10%)
F   13.71 (-2.63%)
GE   85.95 (-2.48%)
DIS   96.12 (-2.78%)
AMC   7.15 (-4.79%)
PYPL   80.55 (+0.59%)
PFE   49.34 (+0.26%)
NFLX   282.60 (-1.03%)

T2 Biosystems - TTOO Stock Forecast, Price & News

$1.64
-0.14 (-7.87%)
(As of 11/28/2022 01:17 PM ET)
Add
Compare
Today's Range
$1.62
$1.76
50-Day Range
$1.58
$127.50
52-Week Range
$1.56
$34.00
Volume
1,295 shs
Average Volume
332,750 shs
Market Capitalization
$11.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.75

T2 Biosystems MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,043.3% Upside
$18.75 Price Target
Short Interest
Bearish
9.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.87mentions of T2 Biosystems in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.58 out of 5 stars

Medical Sector

857th out of 1,040 stocks

Surgical & Medical Instruments Industry

90th out of 103 stocks

TTOO stock logo

About T2 Biosystems (NASDAQ:TTOO) Stock

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Receive TTOO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for T2 Biosystems and its competitors with MarketBeat's FREE daily newsletter.

TTOO Stock News Headlines

BTIG Keeps Their Hold Rating on T2 Biosystems (TTOO)
T2 Biosystems's Earnings Outlook
T2 Biosystems' Survival Riddle
T2 Biosystems (TTOO) Investor Presentation - Slideshow
See More Headlines
Receive TTOO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for T2 Biosystems and its competitors with MarketBeat's FREE daily newsletter.

TTOO Company Calendar

Last Earnings
11/04/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/16/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TTOO
Employees
182
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.75
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+1,043.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-49,240,000.00
Net Margins
-269.09%
Pretax Margin
-269.09%

Debt

Sales & Book Value

Annual Sales
$28.06 million
Book Value
($3.89) per share

Miscellaneous

Free Float
6,820,000
Market Cap
$11.56 million
Optionable
Optionable
Beta
0.21

Key Executives

  • Mr. John J. Sperzel III (Age 59)
    B.Sc., Pres, CEO & Chairman
    Comp: $1.03M
  • Mr. Alec J. Barclay (Age 42)
    Sr. VP & COO
    Comp: $544.43k
  • Mr. Michael Terrence Gibbs Esq.Mr. Michael Terrence Gibbs Esq. (Age 51)
    Sr. VP & Gen. Counsel
    Comp: $527.21k
  • Mr. John M. Sprague CPA (Age 64)
    Chief Financial Officer
  • Ms. Kelley J. Morgan (Age 46)
    Chief People Officer
  • Dr. Aparna Jha Ahuja M.D. (Age 55)
    Chief Medical Officer & Chairman of Scientific Advisory Board
  • Mr. Brett A. Giffin (Age 63)
    Chief Commercial Officer
  • Dr. Roger Smith Ph.D. (Age 57)
    Sr. VP of Science R&D













TTOO Stock - Frequently Asked Questions

Should I buy or sell T2 Biosystems stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TTOO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TTOO, but not buy additional shares or sell existing shares.
View TTOO analyst ratings
or view top-rated stocks.

What is T2 Biosystems' stock price forecast for 2023?

4 brokers have issued 1-year price objectives for T2 Biosystems' stock. Their TTOO share price forecasts range from $2.50 to $35.00. On average, they predict the company's stock price to reach $18.75 in the next twelve months. This suggests a possible upside of 953.3% from the stock's current price.
View analysts price targets for TTOO
or view top-rated stocks among Wall Street analysts.

How have TTOO shares performed in 2022?

T2 Biosystems' stock was trading at $25.81 at the beginning of 2022. Since then, TTOO stock has decreased by 93.1% and is now trading at $1.7801.
View the best growth stocks for 2022 here
.

When is T2 Biosystems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our TTOO earnings forecast
.

How were T2 Biosystems' earnings last quarter?

T2 Biosystems, Inc. (NASDAQ:TTOO) issued its quarterly earnings results on Thursday, November, 4th. The medical equipment provider reported ($4.00) EPS for the quarter, meeting analysts' consensus estimates of ($4.00). The medical equipment provider had revenue of $7.43 million for the quarter. During the same period in the previous year, the business earned ($4.00) EPS.

When did T2 Biosystems' stock split?

T2 Biosystems's stock reverse split on Thursday, October 13th 2022. The 1-50 reverse split was announced on Thursday, October 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems updated its FY 2022 earnings guidance on Wednesday, November, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $22.00 million-$23.00 million, compared to the consensus revenue estimate of $26.33 million.

What is John McDonough's approval rating as T2 Biosystems' CEO?

36 employees have rated T2 Biosystems Chief Executive Officer John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among the company's employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of T2 Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT).

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by a number of retail and institutional investors. Top institutional investors include Altium Capital Management LP (40.28%), Gagnon Securities LLC (10.87%), Bank of New York Mellon Corp (7.64%), Jane Street Group LLC (3.51%), Citadel Advisors LLC (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Adrian M Jones, Alec Barclay, David B Elsbree, Goldman Sachs & Co Llc, John J Sperzel III, John M Sprague, John Mcdonough, Michael Terrence Gibbs and Thomas J Lowery.
View institutional ownership trends
.

How do I buy shares of T2 Biosystems?

Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $1.78.

How much money does T2 Biosystems make?

T2 Biosystems (NASDAQ:TTOO) has a market capitalization of $12.55 million and generates $28.06 million in revenue each year. The medical equipment provider earns $-49,240,000.00 in net income (profit) each year or ($16.45) on an earnings per share basis.

How many employees does T2 Biosystems have?

The company employs 182 workers across the globe.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The official website for the company is www.t2biosystems.com. The medical equipment provider can be reached via phone at (781) 761-4646, via email at ir@t2biosystems.com, or via fax at 781-357-3080.

This page (NASDAQ:TTOO) was last updated on 11/28/2022 by MarketBeat.com Staff